Booster vaccinations and Omicron: the effects on SARS-CoV-2 antibodies in Dutch blood donors

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) booster vaccination campaign and the emergence of SARS-CoV-2 Omicron variants impact the prevalence and levels of SARS-CoV-2 antibodies in the Netherlands. In this study we determined antibody levels across age groups, the impact of Om...

Full description

Saved in:
Bibliographic Details
Published in:BMC infectious diseases 2023-07, Vol.23 (1), p.464-464, Article 464
Main Authors: Quee, F A, Hogema, B M, Slot, E, Kruijer, S, Molier, M, van den Hurk, K, Zaaijer, H L
Format: Article
Language:English
Subjects:
Age
Age groups
Antibodies
Antibodies, Viral
Antibody waning
Blood
Blood & organ donations
Blood donor
Blood Donors
Chronology
Complications and side effects
Coronaviruses
COVID-19
COVID-19 - epidemiology
COVID-19 - prevention & control
COVID-19 diagnostic tests
COVID-19 vaccines
Disease prevention
Disease transmission
Health aspects
Humans
Immunization
Infection
Infections
Infectious diseases
Medical personnel
mRNA
mRNA vaccines
Pathogens
Pharmaceutical industry
Proteins
RNA
SARS-CoV-2
Severe acute respiratory syndrome
Severe acute respiratory syndrome coronavirus 2
Vaccination
Vaccines
Viral diseases
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) booster vaccination campaign and the emergence of SARS-CoV-2 Omicron variants impact the prevalence and levels of SARS-CoV-2 antibodies in the Netherlands. In this study we determined antibody levels across age groups, the impact of Omicron variant infections, and the effect of booster vaccinations on antibody levels. In September and December 2021 and in February 2022, over 2000 Dutch blood donors were tested for presence of SARS-CoV-2 antibodies. Donations were selected based on age, sex, and region of residence, to provide an optimal coverage and representation of the Dutch population. Levels of vaccination-induced spike antibodies decreased over time in all age groups. Donors vaccinated with Janssen or AstraZeneca had significantly lower antibody levels than donors vaccinated with Pfizer or Moderna vaccine. Boostering with an mRNA vaccine elevated antibody levels in all age-groups irrespective of the initial vaccine. In donors aged 
ISSN:1471-2334
1471-2334
DOI:10.1186/s12879-023-08448-w